De novo design by pharmacophore-based searches in fragment spaces

De novo ligand design supports the search for novel molecular scaffolds in medicinal chemistry projects. This search can either be based on structural information of the targeted active site (structure-based approach) or on similarity to known binders (ligand-based approach). In the absence of structural information on the target, pharmacophores provide a way to find topologically novel scaffolds. Fragment spaces have proven to be a valuable source for molecular structures in de novo design that are both diverse and synthetically accessible. They also offer a simple way to formulate custom chemical spaces. We have implemented a new method which stochastically constructs new molecules from fragment spaces under consideration of a three dimensional pharmacophore. The program has been tested on several published pharmacophores and is shown to be able to reproduce scaffold hops from the literature, which resulted in new chemical entities.

[1]  Hongwei Huang,et al.  E-Novo: An Automated Workflow for Efficient Structure-Based Lead Optimization , 2009, J. Chem. Inf. Model..

[2]  Wolfgang Guba,et al.  Integrating molecular design resources within modern drug discovery research: the Roche experience. , 2006, Drug discovery today.

[3]  Gisbert Schneider,et al.  Flux (1): A Virtual Synthesis Scheme for Fragment-Based de Novo Design , 2006, J. Chem. Inf. Model..

[4]  Peter S Kutchukian,et al.  De novo design: balancing novelty and confined chemical space , 2010, Expert opinion on drug discovery.

[5]  Conrad C. Huang,et al.  UCSF Chimera—A visualization system for exploratory research and analysis , 2004, J. Comput. Chem..

[6]  Brian K. Shoichet,et al.  Virtual screening of chemical libraries , 2004, Nature.

[7]  G. Bemis,et al.  BREED: Generating novel inhibitors through hybridization of known ligands. Application to CDK2, p38, and HIV protease. , 2004, Journal of medicinal chemistry.

[8]  M Rarey,et al.  Detailed analysis of scoring functions for virtual screening. , 2001, Journal of medicinal chemistry.

[9]  Mark A. Murcko,et al.  GenStar: A method for de novo drug design , 1993, J. Comput. Aided Mol. Des..

[10]  Harald Mauser,et al.  Chemical Fragment Spaces for de novo Design , 2007, J. Chem. Inf. Model..

[11]  Thierry Langer,et al.  LigandScout: 3-D Pharmacophores Derived from Protein-Bound Ligands and Their Use as Virtual Screening Filters , 2005, J. Chem. Inf. Model..

[12]  Klaus R. Liedl,et al.  One Concept, Three Implementations of 3D Pharmacophore-Based Virtual Screening: Distinct Coverage of Chemical Search Space , 2010, J. Chem. Inf. Model..

[13]  Petra Schneider,et al.  Comparison of correlation vector methods for ligand-based similarity searching , 2003, J. Comput. Aided Mol. Des..

[14]  David A. Pearlman,et al.  CONCEPTS: New dynamic algorithm for de novo drug suggestion , 1993, J. Comput. Chem..

[15]  Matthias Rarey,et al.  On the Art of Compiling and Using 'Drug‐Like' Chemical Fragment Spaces , 2008, ChemMedChem.

[16]  G. Schneider,et al.  Voyages to the (un)known: adaptive design of bioactive compounds. , 2009, Trends in biotechnology.

[17]  Wolfgang Guba,et al.  Recent developments in de novo design and scaffold hopping. , 2008, Current opinion in drug discovery & development.

[18]  J. A. Grant,et al.  A fast method of molecular shape comparison: A simple application of a Gaussian description of molecular shape , 1996, J. Comput. Chem..

[19]  Philip M Dean,et al.  Scaffold hopping in de novo design. Ligand generation in the absence of receptor information. , 2004, Journal of medicinal chemistry.

[20]  Michael M. Hann,et al.  RECAP-Retrosynthetic Combinatorial Analysis Procedure: A Powerful New Technique for Identifying Privileged Molecular Fragments with Useful Applications in Combinatorial Chemistry , 1998, J. Chem. Inf. Comput. Sci..

[21]  Philip M. Dean,et al.  Evaluation of a method for controlling molecular scaffold diversity in de novo ligand design , 1997, J. Comput. Aided Mol. Des..

[22]  R. Kurumbail,et al.  Structural basis for selective inhibition of cyclooxygenase-2 by anti-inflammatory agents , 1996, Nature.

[23]  Gisbert Schneider,et al.  Collection of bioactive reference compounds for focused library design , 2003 .

[24]  John Bradshaw,et al.  Similarity Searching Using Reduced Graphs , 2003, J. Chem. Inf. Comput. Sci..

[25]  C. Dobson Chemical space and biology , 2004, Nature.

[26]  G. Bemis,et al.  The properties of known drugs. 1. Molecular frameworks. , 1996, Journal of medicinal chemistry.

[27]  Richard A. Lewis,et al.  Three-dimensional pharmacophore methods in drug discovery. , 2010, Journal of medicinal chemistry.

[28]  Matthias Rarey,et al.  Similarity searching in large combinatorial chemistry spaces , 2001, J. Comput. Aided Mol. Des..

[29]  Matthias Rarey,et al.  FlexNovo: Structure‐Based Searching in Large Fragment Spaces , 2006, ChemMedChem.

[30]  C. D. Gelatt,et al.  Optimization by Simulated Annealing , 1983, Science.

[31]  Ronald J. Gillespie,et al.  The electron-pair repulsion model for molecular geometry , 1970 .

[32]  Arup K. Ghose,et al.  Atomic physicochemical parameters for three dimensional structure directed quantitative structure-activity relationships. 4. Additional parameters for hydrophobic and dispersive interactions and their application for an automated superposition of certain naturally occurring nucleoside antibiotics , 1989, J. Chem. Inf. Comput. Sci..

[33]  Hans-Joachim Böhm,et al.  The computer program LUDI: A new method for the de novo design of enzyme inhibitors , 1992, J. Comput. Aided Mol. Des..

[34]  Philip M. Dean,et al.  A validation study on the practical use of automated de novo design , 2002, J. Comput. Aided Mol. Des..

[35]  Matthias Rarey,et al.  Recore: A Fast and Versatile Method for Scaffold Hopping Based on Small Molecule Crystal Structure Conformations , 2007, J. Chem. Inf. Model..

[36]  Brian B. Masek,et al.  NovoFLAP: A Ligand-Based De Novo Design Approach for the Generation of Medicinally Relevant Ideas , 2010, J. Chem. Inf. Model..

[37]  G. Superti-Furga,et al.  Structural Basis for the Autoinhibition of c-Abl Tyrosine Kinase , 2003, Cell.

[38]  Philip M. Dean,et al.  A branch-and-bound method for optimal atom-type assignment in de novo ligand design , 1998, J. Comput. Aided Mol. Des..

[39]  Gisbert Schneider,et al.  Searching for drug scaffolds with 3D pharmacophores and neural network ensembles. , 2007, Angewandte Chemie.

[40]  Gisbert Schneider,et al.  Computer-based de novo design of drug-like molecules , 2005, Nature Reviews Drug Discovery.